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R691Structural Biology: Parkin’s
Serpentine Shape Revealed in the
Year of the SnakeParkin is an E3 ubiquitin ligase, mutations in which are responsible for
autosomal recessive juvenile parkinsonism. Recently, several structures of
Parkin have been solved, revealing its serpentine shape and modes of auto-
inhibition.Katja K. Dove and Rachel E. Klevit*
E3 ubiquitin ligases play key roles in
subcellular signaling pathways and
malfunctions in these proteins can
have dramatic effects on human health.
Since the discovery of the E3 ligase
Parkin in 1998, intense efforts to define
its biological function and its role in
the development of Parkinson’s
disease have led to an emerging
picture in which Parkin exists in an
inactive state that must be activated
to localize it to mitochondria and to
unleash its enzymatic activity. Parkin
belongs to a small but important
class of E3 ubiquitin ligases —
RING-between-RING (RBR) E3
ligases — that combine elements of
both RING and HECT E3 ligases to
catalyze substrate ubiquitination [1].
The defining feature and minimal
catalytic unit of RBR E3 ligases is the
RBR domain, which consists of two
Zn2+-binding RING domains (R1 and
R2) and an intervening in-between-ring
(IBR) domain. The mechanism
characteristic of RBR ligases combines
interactions of the R1 domain with
ubiquitin-conjugating enzymes (E2s),
reminiscent of RING-type E3 ligases,
with a subsequent transfer of ubiquitin
onto an active-site cysteine (Cys)
contained within the R2 domain to
form an E3wUb thioester intermediate
(similar to HECT-type E3 ligases). In
addition to its carboxy-terminal RBR
domain, Parkin contains an amino-
terminal ubiquitin-like domain (UblD)
followed by a RING0 (R0) domain that
directly precedes the R1 domain
(Figure 1A) [2]. Given the intense
biomedical interest, it is remarkable
that Parkin has eluded structural
biologists for so long. This may be
due in part to Parkin’s unusually high
Cys content — a feature that
makes generation of homogenous,
recombinant Parkin challenging.
Almost 10% of its amino acids are Cys,
compared with the proteomic averagefrequency of 2%. Of the 35 Cys
residues in human Parkin, 28
coordinate eight Zn2+ ions, Cys431 is
the ligase active site, and the remaining
six have unknown function. The almost
simultaneous report of Parkin
structures by four groups [3–6]
is therefore a significant milestone in
the field.
In these new papers, four crystal
structures of Parkin R0–RBR
constructs have been solved (pdb
4K7D [3], pdb 4I1H and 4I1F [4], pdb
4BM9 [5]), together with a crystal
structure of full-length Parkin at lower
resolution (Figure 1B, pdb 4K95 [3]),
and an NMR structure of the R2
domain (pdb 2LWR [6]). Despite
different crystallization conditions, the
structures are highly similar. The five
structured domains are well defined,
while some of the intervening
sequences between domains lack
density in the crystals, indicative of
disordered protein regions. Several
remarkable features are revealed. First,
the RBR domain does not appear as a
single structural unit that can be viewed
in isolation. Rather than contacting
one another, the R1, IBR, and R2
domains are intertwined with the UblD
and R0 domains to create a Parkin
molecule that is folded back onto itself,
loosely resembling a coiled snake
(Figure 1C,D). Of particular note, R0
(cyan) is inserted between R1 (dark
blue) and R2 (orange) and occludes
the active site on R2 or, in the coiled
snake analogy, Parkin has its ‘fangs’
(i.e., the active site, red spheres
in Figure 1) tucked away under R0
(cyan). This arrangement suggests an
auto-inhibited state, an emerging
theme among RBR E3 ligases [7]. Yet,
the strategies utilized by different RBR
E3 ligases to achieve auto-inhibition
vary. The RBR E3 HHARI has its own
domain (the Ariadne domain) that is
also positioned to occlude the active
site. The Ariadne domain is structurally
distinct from R0 and is positionedcarboxy terminal to the RBR domain
[8]. Another example, the RBR E3
HOIP — a member of the linear
ubiquitin chain assembly complex
known as LUBAC — is auto-inhibited
by an amino-terminal UBA domain,
although the structural details of this
interaction have yet to be elucidated
[9,10]. Clearly, there are numerous
strategies by which the active sites of
RBR E3 ligases are auto-inhibited.
A second remarkable feature is the
linker between the IBR and R2 domains
(amino acids 378–414), most of which
is not visible in the crystal structures,
consistent with it being disordered.
Solution NMR studies confirm its
flexibility [6], emphasizing that the IBR
and R2 domains are able to assume a
range of positions relative to each
other. Intriguingly, a central portion of
the linker (amino acids 391–403; yellow
region in Figure 1) adopts a helical
structure that lies across the putative
E2-binding site on R1. This element is
dubbed a ‘tether’ [4] or ‘REP’ (repressor
element of Parkin) [3], as its position
suggests that it prevents E2 binding.
Indeed, E2 binding is enhanced when
contacts between the REP and R1 are
disrupted bymutations, but a construct
consisting of R1–IBR–REP–R2 is highly
active in auto-ubiquitination assays.
This suggests that the contact between
R1 and REP may serve to modulate
ligase activity rather than inhibit it
completely. Consistent with this notion,
Trempe et al. [3] show by solution NMR
that the R0–RBR Parkin construct as
was crystallized is able to bind to the
E2 UbcH7 with moderate affinity — a
reminder that these crystal structures
are snapshots of a single conformation
of a presumably dynamic molecule.
The structures confirm that the
R0, R1, IBR, and R2 domains each
coordinate two Zn2+ ions [2] and
identify the eight residues in each
domain that serve as ligands. As
predicted, the R1 domain assumes
a fold similar to a canonical RING
domain. The R2 domain, however,
does not resemble a canonical RING
fold, which consists of a characteristic
cross-brace pattern of Zn2+ ligands.
Rather, the R2 domain is similar in
structure to IBR domains, which
sequentially arrange Zn2+-liganding
residues. The R0 domain coordinates
two Zn2+ ions in a hairpin arrangement,
adopting a unique fold that has
previously been dubbed the unique
Parkin domain (UPD) [11]. Although
Figure 1. The structure of Parkin reveals a serpentine shape.
(A) Domain architecture depicting the linear arrangement of the five Parkin domains. The RBR
domain consists of R1–IBR–REP–R2 as indicated by the black bar. (B) A ribbon and (C) sur-
face/mesh representation of the full-length crystal structure of rat Parkin (pdb 4K95, [3]).
Each domain is colored according to the diagram above. In (C), the three domains that
make up the RBR domain (R1, dark blue; IBR, green; and R2, orange; shown as solid surfaces)
are intertwined with the UblD (maroon, mesh) and R0 (cyan, mesh). The active site Cys431
(indicated by the red spheres) is occluded by R0 (cyan). Unstructured linker regions on either
side of the REP (yellow) are not visible in the crystal structure. The connection between IBR
and R2, grey lines (B) or dots (C) were drawn freehand to represent the unstructured linker re-
gions. (D) The structure of Parkin folds back onto itself, loosely resembling a coiled snake.
Each colored segment represents the matching domains using the colors above. The snake
model illustrates that: the active site (mouth of the snake, orange) is hidden behind R0
(cyan); the REP (yellow) contacts R1 (dark blue) at the proposed E2-binding site (not shown);
and the UblD (maroon) binds to the backside of R1. (E) Overlay of the full-length crystal struc-
ture of rat Parkin and the snake model. (We thank Jill M. Hoyt for the drawing of the snake.)
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RING domain, its function is different
in at least one important way: the
R1 domain lacks a critical E3/E2
hydrogen-bonding residue that
typically follows the last Zn2+
-coordinating residue. This interaction
is required for allosteric activation of
E2wUb to transfer ubiquitin to a lysine
residue [12]. Parkin contains a proline
at this position, consistent with the
report that RBR E3 ligases, and
particularly the R1 domain, do not
activate E2wUb conjugates [1,12].
The new studies further validate that
mutations of Cys431 unequivocally
abrogate Parkin activity both in vitro
and in cell-based assays, and they
provide an atomic-level glimpse at
Parkin’s active site, albeit in the context
of an inhibited conformation that
displays low activity in vitro. Several
authors note that His433 and Glu444are in close proximity to Cys431,
identifying a potential catalytic triad
in which the pKa of Cys431 is
suppressed, rendering it highly reactive
[4,5]. Such enhanced intrinsic reactivity
explains the observation that some
minimal R2 constructs of HHARI and
HOIP exhibit some latent activity
in vitro [9,13]. Moreover, it may also
explain why RBR E3 ligases have
evolved to adopt an auto-inhibited
conformation, while their HECT
counterparts are not usually found to
be auto-inhibited. Although mutations
of His433 andGlu444 decrease intrinsic
reactivity of Cys431 in vitro [3–5], only
His433 mutants significantly impair
Parkin function in cell-based assays [4].
Such disparities raise the specter of
conflicting reports of Parkin activity
and function in the literature. There are
likely several reasons that contribute to
these discrepancies. Different Parkinconstructs exhibit variations in activity
levels in vitro and the presence of large
amino-terminal tags can also alter the
level of observed activity [3,5,14].
Furthermore, differences in in vitro and
cell-based assays arise from the dearth
of understanding regarding the
process by which Parkin is activated
in cells. Lazarou et al. [15] have shown
that a ligase-active RBR-only construct
can localize to mitochondria to which
an active-site-dead Parkin is tethered.
However, this process still requires
treatment with the mitochondrial
uncoupler CCCP. This suggests that
simply unleashing the ligase activity
of Parkin is not sufficient for
mitochondrial recruitment, and that
other, still unknown factors aid in
this process. In sum, the previous
experience of the field suggests that
care should be used in the design and
interpretation of experiments using
forms of Parkin other than the
full-length native protein.
Mutations in PARK2 (Parkin) account
for a large fraction of the identified
Parkinson’s disease (PD) mutations,
making them an important target for
drug development. Parkin presents
unique challenges as a drug target as it
is highly complicated from a structural
and functional point-of-view. For
example, PINK1, which is also mutated
at high frequency in PD, encodes a
much larger protein, but the majority of
mutations are harbored within a single
protein domain, the kinase domain. In
contrast, PD-associated mutations in
Parkin are distributed throughout its
five domains, highlighting the
multi-faceted functions of Parkin. The
structure of Parkin in an auto-inhibited
state with its intertwined domains
makes clear that large rearrangements
are required for its catalysis of ubiquitin
transfer. Thus, a given mutation may
affect each Parkin state in a different
way, making it difficult to predict its
consequences.
There are likely four non-mutually
exclusive outcomes of mutations in
Parkin: destabilization or a decrease
in Parkin solubility; decrease in ligase
activity; increase in ligase activity; and
alteration of Parkin’s recruitment to
mitochondria. Destabilizing/solubility
mutations include Zn2+-binding
residues and others that destabilize
the folded Parkin structure [4,6]. Such
mutations can be detrimental by
effectively decreasing the pool of
functional Parkin or may be toxic due
to an increased tendency to aggregate.
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a substitution of active site Cys431.
Other known PD-associated mutations
that decrease Parkin’s ligase activity
in vitro include the putative catalytic
triad R2 residue Glu444 and residues
in R1 that are predicted to affect E2
binding such as Thr240. Mutations that
affect recognition and/or binding of
substrate to Parkin may also manifest
as decreased ligase activity mutants,
although identification of a putative
substrate-binding domain remains
elusive. A PD-associated mutation that
enhances Parkin ligase activity in vitro
occurs at Ala398, located at the
interface between R1 and REP [5].
Other synthetic, structure-based
mutations that disrupt inter-domain
contacts and thereby release
auto-inhibition are Trp403Ala,
Phe463Ala, and Trp183Ala [3–5].
The cellular consequences of
Parkin-activating mutations remain to
be seen. To date, no PD-associated
mutations have been demonstrated
to affect Parkin recruitment to
mitochondria without affecting ligase
activity. Recent advances in the
structural biology of Parkin afford the
ability to understand PD-associated
mutations structurally and confirm
structural outcomes of a variety of
PD-related mutations.
Serendipitously, in the year of the
snake, several structures of Parkin
have been solved, revealing its
serpentine shape. These structures
provide a long overdue foundation on
which to build a sound understanding
of Parkin function both in the
interpretation of current literature and
as a guide for the design of future
studies. The structure suggests that,for Parkin to become an active ligase,
all five of its domains must undergo
substantial rearrangements: R0 must
dissociate fromR2 to expose the active
site; R2 must move towards R1; the
REP must dissociate from R1 to
enhance E2 binding; and the UblD may
have to move away from R1. What
molecular process(es) precipitate(s)
these events (i.e., the uncoiling and
possibly, recoiling of the snake) and the
precise role of each domain remain
questions of fundamental importance
to our understanding of Parkin
function. As the nature of these key
processes becomes clear, future
milestones in the structural biology of
Parkin can hopefully be achieved in
short order.
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